Potential of Anti-influenza Drugs For The Control of High Pathogenicity Avian Influenza in Birds

By: Hunan Huateng Pharmaceutical Co. Ltd.
 
CHANGSHA, China - March 30, 2021 - PRLog -- Scientists have discovered a route of introduction for High Pathogenicity Avian Influenza Virus (HPAIV) H5N8 into Japan and, in parallel, have investigated the potential of two human anti-influenza drugs for the control of HPAI in birds.

Since October 30, 2020, there have been over 30 recorded outbreaks of High Pathogenicity Avian Influenza (HPAI) in domestic poultry and wild fowl in Japan. This outbreak was caused by the influenza A virus H5N8, a known High Pathogenicity Avian Influenza Virus (HPAIV). In such a scenario, identification of the source of the virus and its transmission route is important to control its spread.

A team of scientists led by Professor Yoshihiro Sakoda of Hokkaido University have recently found the probable route of introduction of the current HPAIV into Japan -- by migratory birds from Europe. Separately, they showed that anti-influenza drugs used for humans can potentially be used to treat HPAI in poultry and wild fowl, providing an alternative to culling infected birds. Their findings were published within a week of each other in the journal Viruses.

HPAI is a devastating disease in poultry, leading to large losses both economically and materially. In addition, HPAI is closely related to influenza in humans; certain strains of HPAIV have jumped to humans in the past.

The scientists collected migratory duck feces samples from the lakeside of Lake Komuke, eastern Hokkaido in October 2020. After a number of tests, they confirmed the presence of H5N8 virus in one of the samples.

The scientists also investigated two antivirals, baloxavir marboxil (BXM) and peramivir (PR), used for the treatment of influenza in humans for their potential to treat HPAI in poultry. In their experiments, both drugs improved the survival rate of infected chickens and reduced viral amounts in their organs and feces, with BXM showing higher efficacy. Further work on BXM suggested that an early single-administration of BXM at doses of 2.5 mg/kg or higher would be most effective for the treatment of HPAI in real-life settings.

The next steps would be to confirm if the strain of H5N8 detected by the scientists is responsible for the ongoing HPAI outbreak in Japan, and to verify if BXM is capable of treating HPAI in rare wild birds and poultry farms.

As a leading pharmaceutical intermediates supplier in China, Huateng Pharma provides the services of Anti-Viral intermediates' process development and scale-up production with capacities varying from gram to kilograms and multi tons, such as oseltamivir intermediates, remdesivir intermediates, favipiravir impurities and baloxavir marboxil intermediates, etc.

Hunan Huateng Pharmaceutical Co. Ltd.
Website: https://en.huatengsci.com/
Email:sales@huatengusa.com

Contact
Hunan Huateng Pharmaceutical Co. Ltd.
***@huatengusa.com
End
Source:Hunan Huateng Pharmaceutical Co. Ltd.
Email:***@huatengusa.com
Posted By:***@huatengusa.com Email Verified
Tags:Baloxavir Marboxil
Industry:Business
Location:Changsha - Hunan - China
Subject:Companies
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Huateng Pharma News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share